Patients with multiple sclerosis have high rates of urinary and kidney infections, inpatient hospitalizations, and outpatient hospital claims, according to recent results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting.
High rates of urinary and kidney infections, as well as inpatient hospitalization and outpatient hospital claims, were seen among patients with multiple sclerosis (MS) following a retrospective study of commercial insurance records.
The authors presented their abstract showing these results at this year’s virtual annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. Data for January 2010 through June 2019, which they used in their analysis, came from the IQVIA adjudicated claims database and outcomes were compared between patients with MS (n = 87,755) and controls (n = 87,755) matched 1:1 on age, sex, payer type, Census region, and index year. Risks were investigated pertaining to urinary/kidney, pneumonia/influenza, other respiratory/throat, viral, skin, fungal, and opportunistic infections (eg, pneumocystis pneumonia, cytomegaloviral disease, progressive multifocal leukoencephalopathy, toxoplasmosis, etc).
“It is important to understand risk of specific infections in patients with MS,” the authors said. “However, population-based studies in the United States are rare.”
Their analysis revealed elevated outpatient claims among those with MS vs controls for all infections evaluated:
There was also a greater prevalence of inpatient hospitalizations for all infections among patients with MS vs controls (P < .0001 for all):
Among the patients with MS, the mean (SD) age was 47.3 (10.5) years and all had at least 2 diagnoses of MS (indicated by International Classification of Disease, Ninth Edition, Clinical Modification or ICD-10-CM codes) at least 30 days apart. Controls had 2 diagnoses, at least 30 days apart, for other conditions. Patients were excluded if they had an antibiotic or antiviral claim in the 60 days prior to their baseline visit or had a claim for pregnancy, inpatient residential care, end-stage renal disease facility, HIV, or hepatitis C virus. Most patients in each group (75.7%) were female, 65.7% had commercial insurance, and 34.3% had self-insured employer insurance.
"These findings, from a modern US-based cohort, support an elevated risk for a number of infection types in patients with MS," said lead investigator Riley Bove, MD, of the Weill Institute for Neurosciences at the University of California, San Francisco. “Specifically, the elevated risk of urinary and kidney infections points to a need for better screening and management of bladder function."
A principal limit on these results is that they only represent patients with commercial health insurance, so generalizing them to patients with other insurance types may be difficult. Unmeasured confounders were also possible.
The top reasons given for the higher infection risks seen, especially for urinary and kidney infections, were patients’ immune-suppressing or modulating drugs, MS’ effect on other organ systems, and barriers to care from poor health.
Reference
Bove R, Slaton T, Kozma CM, et al. Risk of specific infections in patients with multiple sclerosis versus matched controls: an analysis of administrative claims data. Presented at: ACTRIMS Forum 2021; February 24-26, 2021. Accessed March 17, 2021. https://www.abstractsonline.com/pp8/#!/9245/presentation/116
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More